Vidya Kesavan
Staff Affiliate - OtherAbout
Copy Link
Titles
Staff Affiliate - Other
Research
Copy Link
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
IRB ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
IRB ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
IRB ID2000025737RoleSub InvestigatorPrimary Completion Date12/31/2029Recruiting ParticipantsEffective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
IRB ID2000029969RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting ParticipantsRandomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
IRB ID2000024170RoleSub InvestigatorPrimary Completion Date01/01/2035Recruiting Participants